Biofrontera Inc (BFRI) - Net Assets
Based on the latest financial reports, Biofrontera Inc (BFRI) has net assets worth $-2.58 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.41 Million) and total liabilities ($18.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Biofrontera Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.58 Million |
| % of Total Assets | -16.74% |
| Annual Growth Rate | N/A |
| 5-Year Change | -23.94% |
| 10-Year Change | N/A |
| Growth Volatility | 77.7 |
Biofrontera Inc - Net Assets Trend (2019–2024)
This chart illustrates how Biofrontera Inc's net assets have evolved over time, based on quarterly financial data. Also explore Biofrontera Inc assets under control for the complete picture of this company's asset base.
Annual Net Assets for Biofrontera Inc (2019–2024)
The table below shows the annual net assets of Biofrontera Inc from 2019 to 2024. For live valuation and market cap data, see market cap of Biofrontera Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $4.43 Million | -7.51% |
| 2023-12-31 | $4.79 Million | -79.93% |
| 2022-12-31 | $23.88 Million | +110.60% |
| 2021-12-31 | $11.34 Million | +94.54% |
| 2020-12-31 | $5.83 Million | +119.31% |
| 2019-12-31 | $-30.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biofrontera Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8723000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | 0.20% |
| Other Components | $121.83 Million | 2748.32% |
| Total Equity | $4.43 Million | 100.00% |
Biofrontera Inc Competitors by Market Cap
The table below lists competitors of Biofrontera Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Uma Exports Limited
NSE:UMAEXPORTS
|
$9.21 Million |
|
Kinovo PLC
LSE:KINO
|
$9.21 Million |
|
ACE LIBERTY+STONE LS -25
F:8MW
|
$9.21 Million |
|
ECOUP OYJ EO 1
F:62H
|
$9.21 Million |
|
Top Shelf International Holdings Ltd
AU:TSI
|
$9.20 Million |
|
Coast Copper Corp
V:COCO
|
$9.20 Million |
|
RENALYTIX PLC LS-0025
F:2O9
|
$9.20 Million |
|
Phoenix Motor Inc. Common Stock
NASDAQ:PEV
|
$9.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biofrontera Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,793,000 to 4,433,000, a change of -360,000 (-7.5%).
- Net loss of 17,759,000 reduced equity.
- New share issuances of 7,662,000 increased equity.
- Other factors increased equity by 9,737,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-17.76 Million | -400.61% |
| Share Issuances | $7.66 Million | +172.84% |
| Other Changes | $9.74 Million | +219.65% |
| Total Change | $- | -7.51% |
Book Value vs Market Value Analysis
This analysis compares Biofrontera Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.34x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-49.72 | $1.08 | x |
| 2020-12-31 | $10.05 | $1.08 | x |
| 2021-12-31 | $13.26 | $1.08 | x |
| 2022-12-31 | $22.59 | $1.08 | x |
| 2023-12-31 | $3.10 | $1.08 | x |
| 2024-12-31 | $0.80 | $1.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biofrontera Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -400.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -47.61%
- • Asset Turnover: 1.69x
- • Equity Multiplier: 4.99x
- Recent ROE (-400.61%) is below the historical average (-224.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -41.95% | 0.91x | 0.00x | $-7.96 Million |
| 2020 | -188.52% | -58.29% | 0.78x | 4.14x | $-11.57 Million |
| 2021 | -332.62% | -156.49% | 0.45x | 4.69x | $-38.85 Million |
| 2022 | -2.68% | -2.23% | 0.56x | 2.13x | $-3.03 Million |
| 2023 | -420.01% | -59.09% | 1.22x | 5.83x | $-20.61 Million |
| 2024 | -400.61% | -47.61% | 1.69x | 4.99x | $-18.20 Million |
Industry Comparison
This section compares Biofrontera Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $236,113,024
- Average return on equity (ROE) among peers: -47.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biofrontera Inc (BFRI) | $-2.58 Million | 0.00% | N/A | $9.20 Million |
| Aurora Cannabis Inc (ACB) | $602.92 Million | -11.50% | 0.39x | $197.35 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $54.20 Million | -73.99% | 0.03x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $1.77 Billion |
| Amphastar P (AMPH) | $639.42 Million | 21.51% | 1.37x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $40.96 Million | 0.73% | 0.09x | $1.80 Billion |
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with t… Read more